文献速递肿瘤 PET/CT核素与放射性配体治疗

[89Zr]Zr-PSMA-617 PET/CT在前列腺癌生化复发中的应用:包含生物分布与剂量估算的先导研究首次临床经验

[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-08-05

该先导研究纳入7例前列腺癌生化复发患者,其中4例[68Ga]Ga-PSMA-11 PET/CT阴性、3例结果不确定,行[89Zr]Zr-PSMA-617 PET/CT在注射后1、24、48、72小时显像。6例患者检出至少1个前列腺癌病灶,尤其在4例[68Ga]Ga-PSMA-11阴性患者中有3例检出病灶;多数肿瘤病灶在24小时首次可见,肿瘤/本底比值随时间持续升高,48小时和72小时所有肿瘤病灶均可检出。

要点

  • 7例生化复发患者中6例经[89Zr]Zr-PSMA-617 PET/CT检出至少1个前列腺癌病灶。
  • 4例[68Ga]Ga-PSMA-11 PET/CT阴性患者中3例在[89Zr]Zr-PSMA-617 PET/CT检出病灶。
  • 多数肿瘤病灶在注射后24小时首次可见,48小时和72小时所有肿瘤病灶均可检出。

核心结论

  • [89Zr]Zr-PSMA-617 PET/CT是一种有前景的新诊断工具,辐射暴露可接受,尤其适用于[68Ga]Ga-PSMA-11 PET/CT未能检出复发病灶的前列腺癌患者。
  • 89Zr的长半衰期使晚期时间点显像(本研究中至72小时)成为可能,肿瘤病灶示踪剂摄取增加、肿瘤/本底比值更高,可识别[68Ga]Ga-PSMA-11 PET/CT上不可见的病灶。

研究设计与样本

  • 先导研究,纳入7例前列腺癌生化复发患者,其中4例[68Ga]Ga-PSMA-11 PET/CT未见异常、3例结果不确定,转诊行[89Zr]Zr-PSMA-617 PET/CT。
  • 注射111 ± 11 MBq(均值±标准差)[89Zr]Zr-PSMA-617后1小时、24小时、48小时和72小时行PET/CT显像。
  • 测定正常器官分布与剂量学,并对视觉上可疑为前列腺癌的病灶进行定量分析。

主要发现

  • 唾液腺、泪腺、肝脏、脾脏、肾脏、肠道和泌尿道可见强烈生理性摄取。
  • 腮腺吸收剂量最高(0.601 ± 0.185 mGy/MBq),其次为肾脏(0.517 ± 0.125 mGy/MBq)。
  • 给予111 MBq时估算全身有效剂量为10.1 mSv(0.0913 ± 0.0118 mSv/MBq)。
  • 6例患者检出至少1个前列腺癌病灶,尤其在4例[68Ga]Ga-PSMA-11 PET/CT阴性患者中有3例检出。
  • 多数肿瘤病灶在注射后24小时首次可见,肿瘤/本底比值随时间持续升高,48小时和72小时所有肿瘤病灶均可检出。

关键数值与推荐

  • 腮腺吸收剂量0.601 ± 0.185 mGy/MBq,肾脏0.517 ± 0.125 mGy/MBq。
  • 给予111 MBq时全身有效剂量10.1 mSv(0.0913 ± 0.0118 mSv/MBq)。
  • 多数肿瘤病灶首次可见时间为注射后24小时,48小时和72小时所有肿瘤病灶均可检出。

临床怎么用

  • 作者认为[89Zr]Zr-PSMA-617 PET/CT是有前景的新诊断工具,尤其当[68Ga]Ga-PSMA-11 PET/CT未能检出复发病灶时。
  • 89Zr的长半衰期支持晚期时间点显像(本研究中至72小时),以提高肿瘤病灶摄取和肿瘤/本底比值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted PET/CT has become increasingly important in the management of prostate cancer, especially in localization of biochemical recurrence (BCR). PSMA-targeted PET/CT imaging with long-lived radionuclides as 89Zr (T1/2 = 78.4 h) may improve diagnostics by allowing data acquisition on later time points. In this study, we present our first clinical experience including preliminary biodistribution and dosimetry data of [89Zr]Zr-PSMA-617 PET/CT in patients with BCR of prostate cancer. METHODS: Seven patients with BCR of prostate cancer who revealed no (n = 4) or undetermined (n = 3) findings on [68Ga]Ga-PSMA-11 PET/CT imaging were referred to [89Zr]Zr-PSMA-617 PET/CT. PET/CT imaging was performed 1 h, 24 h, 48 h, and 72 h post injection (p.i.) of 111 ± 11 MBq [89Zr]Zr-PSMA-617 (mean ± standard deviation). Normal organ distribution and dosimetry were determined. Lesions visually considered as suggestive of prostate cancer were quantitatively analyzed. RESULTS: Intense physiological uptake was observed in the salivary and lacrimal glands, liver, spleen, kidneys, intestine and urinary tract. The parotid gland received the highest absorbed dose (0.601 ± 0.185 mGy/MBq), followed by the kidneys (0.517 ± 0.125 mGy/MBq). The estimated overall effective dose for the administration of 111 MBq was 10.1 mSv (0.0913 ± 0.0118 mSv/MBq). In 6 patients, and in particular in 3 of 4 patients with negative [68Ga]Ga-PSMA-11 PET/CT, at least one prostate cancer lesion was detected in [89Zr]Zr-PSMA-617 PET/CT imaging at later time points. The majority of tumor lesions were first visible at 24 h p.i. with continuously increasing tumor-to-background ratio over time. All tumor lesions were detectable at 48 h and 72 h p.i. CONCLUSION: [89Zr]Zr-PSMA-617 PET/CT imaging is a promising new diagnostic tool with acceptable radiation exposure for patients with prostate cancer especially when [68Ga]Ga-PSMA-11 PET/CT imaging fails detecting recurrent disease. The long half-life of 89Zr enables late time point imaging (up to 72 h in our study) with increased tracer uptake in tumor lesions and higher tumor-to-background ratios allowing identification of lesions non-visible on [68Ga]Ga-PSMA-11 PET/CT imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rosar F, Schaefer-Schuler A, Bartholomä M, et al. [89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates. Eur J Nucl Med Mol Imaging. 2022. PMID: 35930033. doi:10.1007/s00259-022-05925-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。